4D Molecular Therap saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 67 to 76.
This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if 4D Molecular Therap can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock is able to offer and clear a proper buy point.
4D Molecular Therap posted 0% earnings growth in its most recent report, while sales growth came in at -90%.
4D Molecular Therap earns the No. 165 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and Sarepta Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
